INHANCE Stemless Reverse Shoulder IDE
Randomisierte, prospektive, multizentrische Studie des INHANCE Stemless Total Reverse Shoulder System
2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
There is one primary effectiveness endpoint and there are three primary safety endpoints:
-
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative
-
Primary safety endpoint(s):
- No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
- No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
- No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years
The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Florida
-
Atlantis, Florida, Vereinigte Staaten, 33462
- Orthopedic Center of Palm Beach County
-
-
Massachusetts
-
Waltham, Massachusetts, Vereinigte Staaten, 02451
- Boston Bone & Joint Institute BBJI Formerly BSSC
-
-
Michigan
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Trinity Health Grand Rapids
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65201
- Missouri Orthopaedic Institute (MOI)
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28207
- OrthoCarolina Research Institute Charlotte
-
Raleigh, North Carolina, Vereinigte Staaten, 27609
- Duke Orthopaedics of Raleigh
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44333
- Crystal Clinic Orthopaedic Center
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- Lindner Research Center
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Slocum Center for Orthopaedics and Sports Medicine
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- St. Luke's University Health Network
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rothman Orthopaedics Institute
-
-
Tennessee
-
Columbia, Tennessee, Vereinigte Staaten, 38401
- MTBJ a division of Tennessee Orthaepedic Alliance
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84108
- University of Utah
-
-
Virginia
-
Fredericksburg, Virginia, Vereinigte Staaten, 22408
- Mary Washington Orthopedics in affiliation with FOA
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
- Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
- Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
- Individuals who are willing and able to return for follow-up as specified by the study protocol.
- Individuals who are a minimum age of 22 years at the time of consent.
- Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.
Exclusion Criteria:
- BMI > 40 kg/m2
- Individuals have active, uncontrolled local infection or systemic infection.
- Patients who have not reached skeletal maturity, regardless of age.
- Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
- Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
- Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
- Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
- Revision of a failed hemi, total or reverse shoulder arthroplasty.
- Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
- Individuals who are bedridden per the Investigator's determination.
- Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
- Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
- Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
- Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
- Patient has a medical condition with less than 2 years life expectancy.
- Patients who are known to be pregnant or breastfeeding.
- Known polyethylene and/or metal sensitivity or allergy.
- Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
- Otherwise determined by the investigator to be medically unsuitable for participation in this study
- Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: INHANCE Stemless Reverse
INHANCE(TM) Stemless Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
|
Aktiver Komparator: INHANCE Stemmed Reverse
INHANCE(TM) Stemmed Reverse Total Shoulder |
Uncemented Reverse Total Shoulder |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Constant Murley Score (CMS)
Zeitfenster: Pre-op, 2 years
|
Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 2 years
|
|
Removal of any system component
Zeitfenster: 2 year
|
No removal of any system component |
2 year
|
|
Revision of any system component
Zeitfenster: 2 year
|
No revision of any system component |
2 year
|
|
Reoperation of any system component
Zeitfenster: 2 year
|
No reoperation of any system component |
2 year
|
|
Supplemental Fixation of any system component
Zeitfenster: 2 year
|
No supplemental fixation of any system component |
2 year
|
|
Radiolucent Lines (Humeral & Glenoid)
Zeitfenster: 2 year
|
No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones |
2 year
|
|
Migration and Tilt (Humeral & Glenoid)
Zeitfenster: 2 year
|
No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component |
2 year
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Constant Murley Score (CMS)
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
EQ-5D-5L and EQ-VAS
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Survivorship
Zeitfenster: 2 year
|
Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method. |
2 year
|
|
Complications
Zeitfenster: 2 year
|
The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs |
2 year
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Constant Murley Score (CMS)
Zeitfenster: Pre-op, 3-month, 6-month, 1 year
|
Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score. |
Pre-op, 3-month, 6-month, 1 year
|
|
EQ-5D-5L and EQ-VAS
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Simple Shoulder Test
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best). |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Single Assessment Numeric Evaluation (SANE) Score
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal". |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
|
Range of Motion
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year
|
Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative |
Pre-op, 3-month, 6-month, 1 year, 2 year
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- DSM202108
- DSM202108 (Andere Kennung: DePuy Orthopaedics)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .